NCT01091051 - Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

November 30, 2011

Conditions

Palmo-Plantar Pustular PsoriasisPalmo-Plantar Pustulosis

Interventions

DRUG

Ustekinumab

Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20

DRUG

Placebo (Soduim Chloride)

Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20

Trial Locations (8)

Kirk Barber Research, Calgary

Nexus Clinical Research, St. John's

Eastern Canada Cutaneous Research Associates Ltd, Halifax

Lynderm Research, Markham

Windsor Clinical Research Inc., Windsor

Innovaderm Research Inc., Montreal

Centre de Recherches Dermatologiques du Quebec Metropolitain, Québec

Clinique Médicale Dr Isabelle Delorme, Saint-Hyacinthe